Yap, Timothy A <br/><br/>
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Apr 2011 
 - 1271-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2010.31.0367  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--adverse effects<br/>Apoptosis--drug effects<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Biopsy<br/>Cytochrome P-450 CYP2C19<br/>Endothelial Cells--drug effects<br/>England<br/>Female<br/>Focal Adhesion Kinase 1--metabolism<br/>Humans<br/>In Situ Nick-End Labeling<br/>Magnetic Resonance Imaging<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--blood supply<br/>Neoplastic Cells, Circulating--drug effects<br/>Neovascularization, Pathologic--prevention & control<br/>Phosphorylation<br/>Polymorphism, Single Nucleotide<br/>Protein Kinase Inhibitors--adverse effects<br/>Proto-Oncogene Proteins c-met--antagonists & inhibitors<br/>Pyrrolidinones--adverse effects<br/>Quinolines--adverse effects<br/>Receptors, Growth Factor--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Treatment Outcome<br/>Young Adult